GlassScriptPhysician profile
Jennifer Catherine Riske
NPI 1245991314
$2,260.04
in general payments reported to CMS, 2019-2025
22 companies · $611 in 2025
The $611 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $454 · 2023: $458 · 2024: $737 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,805.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $351.88 | 2023-2025 | Soliris |
| Glaxosmithkline, LLC. | $294.65 | 2022-2025 | Benlysta |
| Lundbeck LLC | $124.99 | 2024 | Vyepti |
| Biohaven Pharmaceutical Holding Company LTD. | $124.99 | 2022 | |
| Mayne Pharma Commercial LLC | $122.06 | 2024 | |
| Jazz Pharmaceuticals INC. | $121.89 | 2024 | |
| Catalyst Pharmaceuticals, INC. | $121.08 | 2022 | |
| Alnylam Pharmaceuticals INC. | $119.22 | 2023 | Amvuttra |
| Janssen Pharmaceuticals, INC | $115.40 | 2024 | Spravato |
| Corcept Therapeutics | $92.92 | 2025 | Korlym |
| Amarin Pharma, INC. | $89.21 | 2025 | Vascepa |
| Sage Therapeutics, LLC | $86.12 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $79.27 | 2023 | Farxiga |
| Amgen INC. | $74.15 | 2024 | Evenity, Prolia |
| Pfizer INC. | $67.59 | 2025 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $58.74 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $55.52 | 2025 | Abilify Maintena, Abilify Asimtufii |
| Molnlycke Health Care US, LLC | $50.75 | 2023 | Mepilex Border Flex, Mepilex Border Em, Mepilex Border Sacrum |
| Novo Nordisk INC | $38.72 | 2022 | |
| Axsome Therapeutics, INC. | $33.21 | 2025 | Auvelity |
| Exact Sciences Corporation | $19.83 | 2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.85 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Riske listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.